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Edited by Gerrit van MeerAbstract The discovery and characterization of P-glycoprotein,
an energy-dependent multidrug eﬄux pump, as a mechanism of
multidrug resistance in cancer is generally accepted as a signiﬁ-
cant contribution to the ongoing eﬀort to end death and suﬀering
from this disease. The historical reﬂections of Victor Ling and
Michael Gottesman concerning the early years of this research
highlight the important contributions of the multidisciplinary
teams involved in these studies, and illustrate how technological
developments in biochemistry and molecular and cell biology en-
abled this discovery.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The ﬁrst successful chemotherapy of human cancer led soon
to the realization that drug resistance was going to be a major
impediment to cure or long-term palliation. The simple expedi-
ent of employing multiple cytotoxic drugs with diﬀerent mech-
anisms of action was not the solution to this problem, since
cancers appeared able to develop resistance simultaneously
to many diﬀerent anti-cancer drugs. So the search began for
mechanisms that could account for this multidrug resistance
(MDR) in various cultured cell models, and the search is still
on for which of these mechanisms and/or mechanisms as yet
undiscovered are clinically relevant targets whose circumven-
tion can improve cancer therapy.
Advances in understanding MDR in cancer went hand-in-
hand with development of research tools including the marriage
of biochemistry, molecular biology, somatic cell genetics, and
cell biology that revolutionized all of modern biomedical
research. Table 1 summarizes some of the discoveries about
P-glycoproteins (MDR1 and MDR2(3)) that resulted from this
research. The early story of how these tools were applied to gain
insight into cancer MDR, told from the personal point of view*Corresponding author.
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intellectual inputs from the several groups that were working
on this problem, and the exploitation of state-of-the-art
approaches becoming available as the work was being done.2. The cellular physiology and biochemistry of multidrug
resistance (1968–1986): Victor Ling and colleagues
After my post-doctoral training in Cambridge with Fred
Sanger in 1971, I returned to Toronto to set up my own labo-
ratory at the Ontario Cancer Institute. I wanted to be involved
in the exciting somatic cell genetics program that Lou Siminov-
itch, Jim Till, and Gordon Whitmore had set up. I was partic-
ularly impressed by an earlier publication from that group
showing that it was possible to isolate temperature-sensitive
mutants in mouse L-cells [1]. Although the nature of the defect
was not known at the time, it was eventually localized to a pro-
tein involved in DNA topoisomerase II activity [2]. By the time
I arrived, it had pretty much been decided that the Chinese
hamster ovary (CHO) cells were the cell line of choice. The rea-
sons were that CHO cells maintained a relatively stable and
near normal karyotype in culture, were able to grow in mono-
layer with a high cloning eﬃciency (>50%), could grow in sus-
pension for mass production, could be easily synchronized for
cell-cycle studies, and importantly, stable mutants and temper-
ature-sensitive mutants could be isolated [3,4].
Larry Thompson and Bud Baker were most generous in
‘‘showing me the ropes’’ of how to isolate clones, how to main-
tain mammalian cells in culture, etc. It was team science at its
best. The overarching philosophy of the Toronto somatic cell
genetics group was that the investigation of complex biological
phenomena was best approached by exploiting the power of
genetics – to identify phenotypes that were genetically linked
as opposed to those that were not. A key issue at the time
was to determine whether or not an observed variant pheno-
type was due to a genuine mutation (which could be stably
inherited and used as a genetic marker). In that context, pro-
tocols for isolating variants with freshly cloned cell popula-
tions using single-step selections were developed in order to
maximize the probability of obtaining variants resulting from
single mutations. The same principle was used for isolating
revertants. Luria–Delbru¨ck ﬂuctuation analyses were under-
taken to determine if the appearance of variants was consistent
with spontaneous mutation rates. The use of mutagens result-European Biochemical Societies.
Table 1
Timeline of signiﬁcant discoveries related to MDR1 and MDR2(MDR3)
Date Discovery Reference
1968 Isolation of MDR Chinese hamster cell lines Kessel, D., Botterill, V. and Wodinsky, I. Cancer Res. 28, 938–
941
1970 Demonstration of cytogenetic abnormalities in MDR cells consistent
with gene ampliﬁcation
Biedler, J.L. and Riehm, H. Cancer Res. 30, 1174–1184
1973 Demonstration of increased drug eﬄux in MDR cell lines causing
decreased drug accumulation
Danø, K. Biochem. Biophys. Acta 323, 466–483
1973 Demonstration of inhibition of drug eﬄux causing increased drug
accumulation
Danø, K. op. cit.
1974 Isolation of a series of related colchicine resistant CHO clonal cell lines
using single step selections; Increasing colchicine resistance correlated
with resistance to other drugs and reduced drug uptake
Ling, V. and Thompson, L.H. J. Cell. Physiol. 83, 103–116
1974 Isolation of single-step revertants showing reversion of MDR
phenotype
Ling, V. Can. J. Genet. Cytol. 17, 503–515
1974 Evidence that drug resistance is energy-dependent See, Y.P., Carlsen, S.A., Till, J.E. and Ling, V. Biochem.
Biophys. Acta. 373, 242–252
1976 Demonstration of P-glycoprotein expression in MDR cell lines Juliano, R.L. and Ling, V. Biochim. Biophys. Acta 455, 152–162
1978 MDR shown to be a dominant phenotype Ling, V. and Baker, R.M. Somatic Cell Genet. 4, 193–200
1979 First puriﬁcation of P-gp Riordan, J.R. and Ling, V. J. Biol. Chem. 254, 12701–12705
1979 Isolation of MDR human cancer cell lines Beck, W.T., Mueller, T.J. and Tanzer, L.R. Cancer Res. 39,
2070–2076
1981 Demonstration that verapamil could reverse MDR indicated the
possibility of clinically useful reversing agents for MDR
Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. Cancer Res.
41, 1967–1972
1982 Mechanism of calcium-inﬂux blockers and calmodulin inhibitors for
overcoming resistance is to inhibit drug eﬄux and increase VCR and
ADM accumulation
Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. Cancer Res.
42, 4730–4733
1982 Conﬁrmed dominant phenotype by gene transfer and the DNA transfer
suggested a single or small number of linked genes
Debenham, P.G., Kartner, N., Siminovitch, L., Riordan, J.R.
and Ling, V. Mol. Cell. Biol. 2, 881–889
1983 Various calcium inﬂux blockers, including verapamil, can potentiate
VCR and ADM eﬀects
Tsuruo, T., Iida, H., Nojiri, M., Tsukagoshi, S. and Sakurai, Y.
Cancer Res. 43, 2905–2910
1983 First indication that Pgp is commonly expressed in a variety of MDR
cell lines using Western blots
Kartner, N., Riordan, J.R. and Ling, V. Science 221, 1285–1288
1984 Linking of P-gp and gene transfection and gene ampliﬁcation Robertson, S.M., Ling, V. and Stanners, C.P. Mol. Cell. Biol. 4,
500–506
1984 Quinidine and related compounds also have circumvented drug
resistance
Tsuruo, T., Iida, H., Kitatani, Y., Yokota, K., Tsukagoshi, S.
and Sakurai, Y. Cancer Res. 44, 4303–4307
1984 Demonstration and cloning of common ampliﬁed gene fragments in
Chinese hamster MDR cell lines selected with diﬀerent drugs
Roninson, I.B., Abelson, H.T., Housman, D.E., Howell, N. and
Varshavsky, A. Nature 309, 626–628
1985 Detection of P-gp in clinical samples Bell, D.R., Gerlach, J.H., Kartner, N., Buick, R.N. and Ling, V.
J. Clin. Oncol. 3, 311–315
1985 Ampliﬁcation of P-gp genes in multidrug-resistant mammalian cell
lines
Riordan, J.R., Deuchars, K., Kartner, N., Alon, N., Trent, J.
and Ling, V. Nature 316, 817–819
1985 Isolation of monoclonal antibodies (C219, C494) to P-glycoprotein Kartner, N., Evernden-Porelle, D., Bradley, G. and Ling, V.
Nature 316, 820–823
1985 ABC cassette superfamily deﬁned Higgins, C.F., Hiles, I.D., Whalley, K. and Jamieson, D.J.
EMBO J. 4, 1033–1039
1986 Description of the P-gp/Mdr amplicon Van der Blick, A.M., Van der Velde-Koerts, T., Ling, V. and
Borst, P. Mol. Cell. Biol. 6, 1671–1678
1986 Detection of MDR1 and MDR2(MDR3) genes ampliﬁed in human
cancer cells and cloning of the ﬁrst human mdr sequences
Roninson, I.B., Chin, J.E., Choi, K., Gros, P., Housman, D.E.,
Fojo, A., Shen, D.-W., Gottesman, M.M. and Pastan, I. Proc.
Natl. Acad. Sci. USA 83, 4538–4552
1986 Demonstration of 4.5 kb MDR1 mRNA message in human cell lines of
increasing drug resistance
Shen, D.W., Fojo, A., Chin, J.E., Roninson, I.B., Richert, N.,
Pastan, I. and Gottesman, M.M. Science 232, 643–645
1986 Isolation of P-gp1 probe for overexpressed mRNAs in Chinese hamster
cells
de Bruijn, M.H., Van der Bliek, A.M., Biedler, J.L. and Borst, P.
Mol. Cell. Biol. 6, 4717–4722
Scotto, K.W., Biedler, J.L. and Melera, P.W. Science 232, 751–
755
1986 Cloning of full-length MDR1 gene, demonstration of its homology to
bacterial ATP-dependent transporters, and overall structure
Gros, P., Croop, J. and Housman, D.E. Cell 47, 371–390
Chen, C.-J., Chin, J.E., Ueda, K., Clark, D., Pastan, I.,
Gottesman, M.M. and Roninson, I.B. Cell 47, 381–389
1986 Cloning of the ﬁrst mdr coding sequence and demonstration of 5 kb
mdr mRNA message in multidrug-resistant hamster cell lines
Gros, P., Croop, J., Roninson, I., Varshavsky, A. and Housman,
D.E. Proc. Natl. Acad. Sci. USA 83, 337–341
1986 Model of P-gp as an export pump by analogy to HlyB Gerlach, J.H., Endicott, J.A., Juranka, P.F., Henderson, G.,
Sarangi, F., Deuchars K.L. and Ling, V. Nature 324, 485–489
1986 MDR1 encodes P-glycoprotein Ueda, K., Cornwell, M.M., Gottesman, M.M., Pastan, I.,
Roninson, I.B., Ling, V. and Riordan, J.R. Biochem. Biophys.
Res. Commun. 141, 956–962
1986 Full-length MDR1 cDNA confers multidrug resistance Gros, P., Ben-Neriah, Y., Croop, J.M. and Housman, D.E.
Nature 323, 728–731
1986 Anti-P-gp MoAb MRK-16, to an external epitope, reverses drug
resistance
Hamada, H. and Tsuruo, T. Proc. Natl. Acad. Sci. USA 83,
7785–7789
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1986 Membranes containing P-glycoprotein bind drugs (e.g., vinblastine) Cornwell, M.M., Gottesman, M.M. and Pastan, I. J. Biol.
Chem. 262, 7921–7928
1986 Photoaﬃnity labeling of P-gp Cornwell, M.M., Safa, A.R., Felsted, R.L., Gottesman, M.M.
and Pastan, I. Proc. Natl. Acad. Sci. USA 83, 3847–3851
1987 Expression pattern of MDR mRNA in normal tissues and human
cancers
Fojo, A.T., Ueda, K., Slamon, D.J., Poplack, D.G.,
Gottesman, M.M. and Pastan, I. Proc. Natl. Acad. Sci. USA
84, 265–269
1987 P-gp is phosphorylated by C-kinase. The phosphorylation is inhibited
by verapamil and triﬂuoperazine and is enhanced by C-kinase activator
Hamada, H., Hagiwara, K.I., Nakajima, T. and Tsuruo, T.
Cancer Res. 47, 2860–2865
1987 MDR1 is a real gene, mainly expressed in the liver Van der Bliek, A.M., Baas, F., Ten Houte de Lange, T.,
Kooiman, P.M., Van der Velde-Koerts, T. and Borst, P.
EMBO J. 6, 3325–3331
1987 Expression pattern of P-gp in normal tissue by immunohistochemistry Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M.,
Pastan, I. and Willingham, M.C. Proc. Natl. Acad. Sci. USA
84, 7735–7738
1987 Identiﬁcation of human MDR1 promoter Ueda, K., Pastan, I. and Gottesman, M.M. J. Biol. Chem. 262,
17432–17436
1988 Explains why P-gp was not detected using boiled samples on Laemmli
gels because of the unusual nature of P-gp
Greenberger, L.M., Scott, W.S., Georges, E., Ling, V. and
Horwitz, S.B. J. Natl. Cancer Inst. 80, 506–510
1988 P-gp expression in normal tissue revealed; Positive tissues are adrenal
cortex and medulla, renal tubules and placenta
Sugawara, I., Kataoka, I., Morishita, Y., Hamada, H.,
Tsuruo, T., Itoyama, S. and Mori, S. Cancer Res. 48, 1926–
1929
1988 Point mutations in MDR1 change substrate speciﬁcity Choi, K., Chen, C.-J., Kreigler, M. and Roninson, I.B. Cell 53,
519–529
1988 Retroviral vectors encoding MDR1 can confer MDR whose expression
is apical in polarized epithelium
Pastan, I., Gottesman, M.M., Ueda, K., Lovelace, E.,
Rutherford, A.V. and Willingham, M.C. Proc. Natl. Acad. Sci.
USA 85, 4486–4490
1988 Use of MDR1 vectors for co-transfection and selection of unselected
genes
Kane, S.E., Troen, B.R., Gal, S., Ueda, K., Pastan, I. and
Gottesman, M.M. Mol. Cell. Biol. 8, 3316–3321
1988 Transport of drugs by P-gp in isolated vesicles Horio, M., Gottesman, M.M. and Pastan, I. Proc. Natl. Acad.
Sci. USA 85, 3580–3584
1988 P-gp was homogenously puriﬁed by aﬃnity chromatography using
MRK-16. Puriﬁed P-gp has an ATPase activity
Hamada, H. and Tsuruo, T. J. Biol. Chem. 263, 1454–1458
1989 P-gp is expressed in brain capillaries Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M.,
Pastan, I. and Willingham, M.C. J. Histochem. Cytochem. 37,
159–164
1989 MDR-reversal mechanism of verapamil clariﬁed; Verapamil actually
binds to P-gp and can be transported by P-gp
Yusa, K. and Tsuruo, T. Cancer Res. 49, 5002–5006
1989 Mice expressing MDR1 in bone marrow are drug-resistant Galski, H., Sullivan, M., Willingham, M.C., Chin, K.-V.,
Gottesman, M.M., Pastan, I. and Merlino, G.T. Mol. Cell.
Biol. 9, 4357–4363
1990 Detection of P-gp isoforms by gene speciﬁc monoclonal antibodies Georges, E., Bradley, G., Gariepy, J. and Ling, V. Proc. Natl.
Acad. Sci. USA 87, 152–156
1990 Reverse-transcription PCR analysis demonstrates widespread MDR1
expression in human cancers
Noonan, K.E., Beck, C., Holzmayer, T.A., Chin, J.E.,
Wunder, J.S., Andrulis, I.L., Gazdar, A.F., Willman, C.L.,
Griﬃth, B., Von Hoﬀ, D.D. and Roninson, I.B. Proc. Natl.
Acad. Sci. USA 87, 7160–7164
1990 Genetic demonstration of distinct P-gp sites responsible for drug
binding and release
Safa, A.R., Stern, R.K., Choi, K., Agresti, M., Tamai, I.,
Mehta, N.D. and Roninson, I.B. Proc. Natl. Acad. Sci. USA
87, 7225–7229
1990 Full-length sequence of mouse mdr2(mdr3) gene Devault, A. and Gros, P. Mol. Cell. Biol. 10, 1652–1663
1990 Hormone (progesterone)-regulated expression of P-gp Arceci, R.J., Baas, F., Raponi, R., Horwitz, S.B., Housman,
D. and Croop, J.M. Mol. Reprod. Dev. 25, 101–109
1990 ATPase activity of P-gp Germann, U.A., Willingham, M.C., Pastan, I. and Gottesman,
M.M. Biochemistry 29, 2295–2303
1990 Hydrophobic vacuum cleaner model Raviv, Y., Pollard, H.B., Bruggemann, E.P., Pastan, I. and
Gottesman, M.M. J. Biol. Chem. 265, 3975–3980
1990 MDR-like genes in model organisms (e.g., L. tarentolae) Ouellette, M., Fase-Fowler, F. and Borst, P. EMBO J. 9, 1027–
1033
1991 Correlation of P-gp with outcome in children’s cancer Chan, H.S.L., Haddad, G., Thorner, P.S., DeBoer, G., Lin,
Y.P., Ondrusek, N., Yeger, H. and Ling, V. N. Engl. J. Med.
325, 1608–1614
1991 MDR-like genes in model organisms (e.g., C. elegans, D. melanogaster) Wu, C.T., Budding, M., Griﬃn, M.S. and Croop, J.M. Mol.
Cell. Biol. 11, 3940–3948
Schinkel, A.H. and Borst, P. Semin. Cancer Biol. 2, 213–226
1991 P-gp expression in bone marrow stem cells explains the ‘‘side
population’’ eﬀect seen in these cells with ﬂuorescent dyes
Chaudhary, P.M. and Roninson, I.B. Cell 66, 85–94
1992 Drug-stimulated ATPase of reconstituted P-gp; Vanadate inhibition Ambudkar, S.V., Lelong, I.H., Zhang, J., Cardarelli, C.O.,
Gottesman, M.M. and Pastan, I. Proc. Natl. Acad. Sci. USA
89, 8472–8476
1992 P-gp is directly involved in blood–brain barrier Tatsuta, T., Naito, M., Ohhara, T., Sugawara, I. and Tsuruo,
T. J. Biol. Chem. 267, 20383–20391
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Date Discovery Reference
1992 Retroviral transfer of MDR1 into bone marrow confers in vivo drug
resistance
Sorrentino, B.P., Brandt, S.J., Bodine, D., Gottesman, M.M.,
Pastan, I., Cline, A. and Nienhuis, A.W. Science 257, 99–103
1993 Epigenetic induction of MDR1 expression by transient exposure to
diﬀerent chemotherapeutic drugs
Chaudhary, P.M. and Roninson, I.B. J. Natl. Cancer Inst. 85,
632–639
1993 MDR2 shown to be essential for transport of phosphatidylcholine in
liver
Smit, J.J., Schinkel, A.H., Oude Elferink, R.P., Groen, A.K.,
Wagenaar, E., van Deemter, L., Mol, C.A., Ottenhoﬀ, R.,
van der Lugt, N.M. and van Roon, M.A., et al. Cell 75, 451–
462
1994 MDR1 knock out mouse has blood–brain barrier defects and
alterations in pharmacokinetics of drugs
Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H.,
Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk,
M.A., Robanus-Maandag, E.C. and te Riele, H.P., et al. Cell
77, 491–502
1994 Puriﬁcation and reconstitution showing that P-gp can act alone to
transport drugs
Shapiro, A.B. and Ling, V. J. Biol. Chem. 269, 3745–3754
Shapiro, A. and Ling, V. (1995) J. Biol. Chem. 270, 16167–
16175
1995 Use of orthovanadate to trap P-gp in the post-hydrolysis transition
state
Urbatsch, I.L., Sankaran, B., Weber, J. and Senior, A.E. J.
Biol. Chem. 270, 19383–19390
1996 Clinical use of a reversing agent Chan, H.S.L., DeBoer, D., Thiessen, J.T., Kingston, J.E.,
O’Brien, J.M., Koren, G., Giesnrecht, E., Haddad, G., Verjee,
Z., Hungerford, J.L., Ling, V. and Gallie, B.L. Clin. Cancer
Res. 2, 1499–1508
1996 Evidence that MDR2(MDR3) confers drug resistance Kino, K., Taguchi, Y., Yamada, K., Komano, T. and Ueda,
K. FEBS Lett. 399, 29–32
1996 Use of a ‘‘cys-less’’ mutant of P-gp and crosslinking agents to map the
drug binding sites
Loo, T.W. and Clarke, D.M. J. Biol. Chem. 271, 27482–27487
1997 Use of 99m Tc-sestamibi uptake into tumors as a surrogate marker for
P-gp function detectable by whole body imaging
Luker, G.D., Facasso, P.M., Dobkin, J. and Piwnica-Worms,
D. J. Nucl. Med. 38, 369–372
1997 Evidence that there are at least two and probably more drug-binding
sites on P-gp
Dey, S., Ramachandra, M., Pastan, I., Gottesman, M.M. and
Ambudkar, S.V. Proc. Natl. Acad. Sci. USA 94, 10594–10599
Shapiro, A.B. and Ling, V. Eur. J. Biochem. 250, 130–137
1997 Gene rearrangement as a novel mechanism for MDR1 gene activation Mickley, L.A., Spengler, B.A., Knutsen, T.A., Biedler, J.L.
and Fojo, T.J. Clin. Invest. 99, 1947–1957
1997 Drug-transporting P-gp is not essential in metabolism, as long as mice
are kept away from xenotoxins
Schinkel, A.H., Mayer, U., Wagenaar, E., Mol, C.A., van
Deemter, L., Smit, J.J., van der Valk, M.A., Voordouw, A.C.,
Spits, H., van Tellingen, O., Zijlmans, J.M., Fibbe, W.E. and
Borst, P. Proc. Natl. Acad. Sci. USA 94, 4028–4033
1997 P-gp is a major factor in reducing the oral availability of amphipathic
drugs, as exempliﬁed by Taxol
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A.H.,
Smit, J.W., Meijer, D.K., Borst, P., Nooijen, W.J., Beijnen,
J.H. and van Tellingen, O. Proc. Natl. Acad. Sci. USA 94,
2031–2035
Mechetner, E.B., Schott, B., Morse, B.S., Stein, W.D., Druley,
T., Davis, K., Tsuruo, T. and Roninson, I.B. Proc. Natl. Acad.
Sci. USA 94, 12908–12913
1997 P-gp has multiple drug binding sites that interact with each other Shapiro, A.B. and Ling, V. Eur. J. Biochem. 250, 130–137
1997 P-gp recognizes drugs from the inner leaﬂet consistent with a
hydrophobic vacuum model
Shapiro, A.B. and Ling, V. Eur. J. Biochem. 250, 122–129
1998 Demonstration that P-gp inhibits apoptosis through a mechanism
unrelated to drug eﬄux in lymphoid cells
Smyth, M.J., Krasovskis, E., Sutton, V.R. and Johnstone,
R.W. Proc. Natl. Acad. Sci. USA 95, 7024–7029
1998 Mechanism of action: cooperativity between two ATP sites in MDR1 Senior, A.E. and Bhagat, S. Biochemistry 37, 831–836
1998 Mechanism of action: P-gp shows reduced aﬃnity for photoaﬃnity
analog of drug-substrate in the Vi trapped transition state: a surrogate
assay to monitor conversion of high aﬃnity ‘‘ON’’ site to a low aﬃnity
‘‘OFF’’ site
Ramachandra, M., Ambudkar, S.V., Chen, D., Hrycyna, C.A.,
Dey, S., Gottesman, M.M. and Pastan, I. Biochemistry 37,
5010–5019
1999 Use of inhibition of rhodamine 123 eﬄux as a surrogate assay for P-gp
inhibition in CD56 peripheral mononucleate cells in clinical trials
Robey, R., Bakke, S., Stein, W., Meadows, B., Litman, T.,
Patil, S., Smith, T., Fojo, T. and Bates, S. Blood 93, 306–314
1999 Proposal that P-gp mediated ATP hydrolysis could be used both for
transport and to ‘reset’ the molecule
Hrycyna, C.A., Ramachandra, M., Germann, U.A., Cheng,
P.W., Pastan, I. and Gottesman, M.M. Biochemistry 38,
13887–13899
2000 MDR2(MDR3) gene can confer resistance to real anti-cancer drugs Smith, A.J., van Helvoort, A., van Meer, G., Szabo, K.,
Welker, E., Szakacs, G., Varadi, A., Sarkadi, B. and Borst, P.
J. Biol. Chem. 275, 23530–23539
2000 Mechanism of action: ATP hydrolysis needed to power transport and
restore ability of P-gp molecule to bind substrate
Sauna, Z.E. and Ambudkar, S.V. Proc. Natl. Acad. Sci. USA
97, 2515–2520
2001 Mechanism of action: drug transport is driven by ATP binding while
ATP hydrolysis resets the molecule
Rosenberg, M.F., Velarde, G., Ford, R.C., Martin, C.,
Berridge, G., Kerr, I.D., Callaghan, R., Schmidlin, A.,
Wooding, C., Linton, K.J. and Higgins, C.F. EMBO J. 20,
5615–5625
2001 Clinical trial showing survival advantage for patients with AML
treated with MDR inhibition plus chemotherapy
List, A.F., Kopecky, K.J., Willman, C.L., Head, D.R.,
Persons, D.L., Slovak, M.L., Dorr, R., Karanes, C., Hynes,
H.E., Doroshow, J.H., Shurafa, M. and Appelbaum, F.R.
Blood 98, 3212–3220
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2002 Use of an MDR1 vector to force expression of a non-selectable co-
transfected gene in vivo
Licht, T., Haskins, M., Henthorn, P., Kleiman, S.E., Bodine,
D.M., Whitwam, T., Puck, J.M., Gottesman, M.M. and
Melniczek, J.R. Proc. Natl. Acad. Sci. USA 99, 3123–3128
2004 Global prediction of MDR1 substrates, inhibitors and collateral
sensitizers
Szakacs, G., Annereau, J.P., Lababidi, S., Shankavaram, U.,
Arciello, A., Bussey, K.J., Reinhold, W., Guo, Y., Kruh, G.,
Reimers, M., Weinstein, J.N. and Gottesman, M.M. Cancer
Cell 6, 129–137
1002 M.M. Gottesman, V. Ling / FEBS Letters 580 (2006) 998–1009ing in increased frequency of variants was additional evidence
for a genetic basis for the variant phenotype. Cell–cell hybrids
were used to determine if a phenotype was dominant or reces-
sive. The transfer of a variant phenotype to recipient cells
using chromosome transfer or DNA transfection was addi-
tional evidence that the variant phenotype had a genetic basis.
The colchicine-resistant cell lines in Chinese hamster ovary
(CHO) cells were developed in that milieu [5,6].
The original purpose for isolating variant cell lines resistant
to colchicine was to obtain mutants with altered colchicine-
binding protein (tubulin) as an initial approach towards cre-
ating a class of cell division mutants. Clonal selections were
undertaken in single steps without mutagen to minimize mul-
tiple changes. Higher levels of colchicine resistance were se-
lected from clonal populations of lower resistance. Mutagen
was used in some of these steps in order to increase the fre-
quency and variety of variants obtained. Surprising to us was
that of more than 20 colchicine-resistant clonal lines charac-
terized, all had a pleiotropic cross-resistance to unrelated
drugs such as daunomycin and puromycin, drugs not known
to interact with microtubules, and all had reduced colchicine
uptake into whole cells proportionate to the degree of drug
resistance while the colchicine-binding ability of the mutant
cell extracts was not signiﬁcantly reduced. We concluded
from this study that, ‘‘colchicine resistance most probably
stems from alteration(s) in the cell resulting in reduced perme-
ability [5]’’.
Unbeknown to us, after we submitted our CHRmutant paper
[5], Keld Danø submitted his elegant study of the kinetics of
daunomycin uptake in resistant mouse Ehrlich ascites tumor
cells [7]. He showed that the accumulation of daunomycin
reached a lower steady-state in the resistant cells compared with
the wild-type cells while the uptake into the isolated nuclei from
these cells was similar. Moreover, the steady-state of labeled
daunomycin increased in the presence of metabolic inhibitors
such as 2-deoxyglucose, and also in the presence of structural
analogs such as N-acetyldaunomycin. These observations
along with the fact that the accumulated steady-state level of
daunomycin increased in the presence of Vinca alkaloids, to
which the tumor cells were cross-resistant, led Danø to con-
clude that the reduced accumulation of the drugs must be due
to an energy-dependent carrier-mediated extrusion mechanism
and that the V. alkaloids competed with daunomycin for the
extrusion mechanism.
Y.P. See, a post-doctoral fellow in my lab, had also exam-
ined the energy dependence of colchicine accumulation in the
CHR cell lines [8]. He observed that in the absence of glucose
a number of metabolic inhibitors such as azide and cyanide
greatly stimulated the rate of colchicine uptake (up to 100-
fold) in the CHR cells. This was also observed with unrelated
drugs (e.g., actinomycin D, and puromycin) and this increased
uptake could be rapidly reversed by the addition of metaboliz-able sugars such glucose or ribose [8]. We speculated and later
conﬁrmed that these rapid drug uptake changes correlated
with the rapid changes in the level of ATP in the cell [9].
Although our results were consistent with the conclusions of
Danø, we felt at the time that the highly pleiotropic nature
[10] of the MDR phenotype (e.g., cross-resistance to unrelated
drugs and increased or collateral sensitivity to many mem-
brane active agents) could not be explained easily by a classical
drug eﬄux mechanism. We found it diﬃcult to envision how a
single transporter could recognize so many diﬀerent com-
pounds! At the same time, our study of initial rates of colchi-
cine uptake under diﬀerent conditions provided evidence that
colchicine enters cells via an unmediated diﬀusion process.
For example, we could not compete for colchicine uptake with
the close structural analog colcemid. Also ‘‘ﬂuidizers’’ of the
membrane lipid bilayer such as non-ionic detergents and local
anesthetics were able to stimulate drug uptake and reverse the
drug resistance phenotype [5,9]. Moreover, when we measured
the activation energies of colchicine uptake using Arrhenius
plots in wild-type CHO cells in the presence of potassium cya-
nide (stimulated rate) or in its absence (normal rate), they were
similar at 20 and 19 kcal per mole, respectively [11], suggesting
that the mechanism of colchicine uptake, at least in wild-type
cells, was similar in the presence or absence of the energy-
dependent mechanism.
All this suggested to us that a more global eﬀect on the cell
membrane must be postulated in order to accommodate the
MDR phenotype and we felt this would be more consistent
with an ‘‘active’’ permeability barrier model. We suggested
that a ‘‘modulator’’ of membrane lipid ﬂuidity, perhaps involv-
ing phosphorylation/dephosphorylation of membrane pro-
teins, could be the basis of such a model [6,9]. This model
stimulated a lot of discussion and in a membrane meeting Da-
vid Goldman’s question was particularly insightful [11]. David
raised the question of a carrier-mediated mechanism after
some other queries:
Alper: If you are using the same carrier for colchicine and other
things, would you not expect to ﬁnd competition if you look, say
at colchicine uptake and then use actinomycin at the same time?
Ling:We looked at this closely and could ﬁnd no competition be-
tween colchicine and puromycin, for example.
. . . . . . . . . . . . . . . . . . . . .
Goldman: Could you not have a carrier system with a very high
Km?
Ling: One could. You would also have to postulate that this car-
rier is located on the membrane and that this carrier has speciﬁc-
ity for a wide variety of compounds.’’
Twenty years later Adam Shapiro from my lab showed that
P-glycoprotein (P-gp) recognizes its substrates from the lipid
bilayer of the plasma membrane, from the inner leaﬂet, and
since these substrates are hydrophobic in nature, they would
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the Km for P-gp transport of these compounds could well be
very high! [12,13]. This also forms the basis for the ‘‘hydropho-
bic vacuum’’ model of P-gp [14,15].
While the characterization of the MDR phenotype was on-
going we continued to investigate the genetic relationship be-
tween the CHR and the MDR phenotype. It should be noted
that by the early 1970s a number of cell lines and transplan-
table tumors selected for resistance to anti-cancer drugs and
having reduced drug uptake had been reported by various
investigators (for example, Refs. [7,16–18]). These were not
clonal lines nor were they selected with the goal of minimizing
genetic changes, so multiple genetic changes were possible.
We reasoned that if there were multiple mechanisms for the
MDR phenotype, a variety of well-characterized independent
isolates of CHR mutants would be useful for delineating the
diﬀerent mechanisms [8]. However, further genetic character-
ization convinced us that the MDR phenotype was intimately
linked to colchicine resistance (CHR) and likely the result of a
single gene alteration (or at least due to closely linked genes).
In addition to the independently selected CHR clones that all
displayed the MDR phenotype, cell: cell hybrid studies
showed that the MDR phenotype paralleled the CHR pheno-
type in being expressed in an incompletely dominant fashion
[5,19]. Moreover, independent revertant clones selected in a
single step from the two highly resistant lines (CHR C5 and
CHR C4) using tritiated leucine to kill puromycin-resistant
CHR cells which incorporated the labeled leucine in the pres-
ence of puromycin while the revertant puromycin-sensitive
cells did not, also showed that the MDR and the CHR phe-
notype both co-reverted [6]. Finally, when cellular DNA
transfer technology using calcium phosphate-precipitated
DNA was developed, [20], we showed that genomic DNA
from cells transfected into drug-sensitive mouse L-cells re-
sulted in the expression of both the CHR and MDR pheno-
types [21]. Because in such a system very little donor DNA
is retained in the recipient cell and non-linked genes are not
normally co-transferred, we again concluded that both the
CHR and MDR phenotypes are the result of a single gene
mutation.
I have gone into some detail with respect to the ‘‘somatic
cell’’ genetic investigation of the CHR phenotype, because it
led us to the fundamental premise that a single genetic alter-
ation was the most likely explanation for the complex MDR
phenotype. When P-gp was later discovered, and its level of
expression varied with the drug resistance phenotype in the
‘‘genetically deﬁned’’ cell lines (independent isolated clones,
revertants, DNA transfectants, etc.), we were fully convinced
that it must play a critical and likely causative role. In many
respects, these well-characterized lines allowed us to deﬁne
P-gp functionally before its primary sequence was known.
We were fortunate to have a strong membrane biology com-
munity at the University of Toronto. When Rudy Juliano, a
young faculty member in Biophysics in Aser Rothstein’s group
at the Research Institute, Hospital for Sick Children, heard
about our CHR permeability ‘‘membrane’’ mutant cells, he
proposed to investigate the cells with the recently developed
labeling technique to label cell-surface carbohydrates using
galactose oxidase-[3H]-borohydride [22,23]. That was a deﬁn-
ing moment – when we saw a very prominent 165000 MW
peak, signiﬁcantly larger than any other peak in the gel. This
peak was observed in CHR mutants, not in wild-type cells,and it was greatly reduced in revertant cells. Moreover, it
was present in an actinomycin D Syrian hamster line. We
called it P-glycoprotein (P-gp) because of its association with
colchicine permeability.
In those early cell surface-labeling experiments, a dramatic
increase in the actual amount of amino acid labeled protein
could not be demonstrated. Although we did not know the
reasons for this, we speculated that the prominent surface
labeling in mutant cells could be due to some general confor-
mation change on the cell plasma membrane exposing more
carbohydrates rather than the result of increased synthesis,
consistent with the notion of a pleiotropic alteration. Of
interest also was the fact that Rudy used the Fairbanks gel
system to detect P-gp where the sample was dissolved in
SDS and urea [24], a system favored by membrane biochem-
ists at that time. We did not realize until much later how
important the choice of the gel separation system was for
detecting P-gp. Lee Greenberger and Susan Horwitz took
the initiative to determine if the ‘‘P-glycoproteins’’ they de-
tected in their mouse cell line were diﬀerent from the CHO
cell P-gp. In a collaborative study, Lee showed that P-gp
was detected with a much lower eﬃciency when prepared
for separation in the more popular Laemmli gel system
(SDS plus heating) compared with the Fairbanks system
[25]. Apparently, the heating step caused the amount of P-
gp detected to be greatly reduced in the Laemmli system,
while this was not the case in the Fairbanks system. This fact
may have prevented many from detecting the presence of P-
gp in their system.
Jack Riordan at the Hospital for Sick Children approached
us to purify P-gp using his membrane biochemistry expertise.
He isolated plasma membrane vesicles (PMVs) from the series
of mutants and revertants and showed that PMVs from the
highly resistant CHR C5 cells contained a prominent Coomas-
sie blue stained band at about 170000 molecular weight re-
solved by Fairbanks gel electrophoresis. This band was less
prominent in the less resistant CHR C4 cells and not present
or barely detectable in the wild-type or revertant cells [26].
Extraction of the PMVs with various mild agents showed that
P-gp could not be extracted with other membrane peripheral
proteins so it was likely an integral membrane protein. It
could be solubilized with non-ionic detergents and greatly en-
riched using a series of lectin aﬃnity columns to a level of
purity such that it was easily the major band in the SDS gel
with some contaminating minor bands. This was another
deﬁning moment, as it showed for the ﬁrst time clear bio-
chemical evidence that P-gp is localized in the plasma mem-
brane, that it is present in signiﬁcant amounts (estimated to
be 3–4% of total plasma membrane protein) in a highly colchi-
cine-resistant line and that the amount of this protein in the
plasma membrane correlated with the level of colchicine resis-
tance. Moreover, it raised the possibility that it might be pos-
sible to use the isolated PMVs for in vitro drug uptake studies
and that the protein could be puriﬁed for reconstitution stud-
ies and used to raise antisera. Norbert Kartner was involved
in that work as a research assistant in Jack’s lab and he
caught the P-gp ‘‘bug’’. He applied to work as a graduate stu-
dent in my lab, thereby cementing the collaboration between
our two labs.
Norbert decided to generate rabbit antisera directed against
the cell surface components of the multidrug-resistant human
CEM/VLB100 cell line selected for resistance to vinblastine
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line to improve the sensitivity and speciﬁcity of detecting P-
gp [28]. To our delight, the antisera detected P-gp in diﬀerent
MDR cell lines from diﬀerent species isolated with diﬀerent
drugs. He used a Western blot analysis to show all these lines
had one membrane component in common, a 170000 MW
component that increased with the level of drug resistance –
P-gp. In fact, when the antiserum raised against the human
CEM/VLB100 cell line was used against CHO cell membranes
of diﬀerent levels of drug resistance, the only component de-
tected was P-gp. The antiserum did not detect any other mem-
brane component. This was another deﬁning moment, as we
could now quantify with some degree of accuracy the amount
of P-gp expressed to correlate with other phenomena. In this
context, the Western blot analysis of the L-cells transfected
with genomic DNA from CHR C5 cells [21] expressed P-gp;
moreover, the level of expression correlated with the degree
of colchicine resistance and with the number of double minute
chromosomes (DMs) [29]. Since DMs are associated with gene
ampliﬁcation, we predicted that the P-gp gene was ampliﬁed in
the transfected cells and possibly in other selected MDR cell
lines [28,29]. We speculated also that it should be possible to
clone the P-gp gene from isolated DMs, as Caizzi and Bostock
[30] had done in cloning ampliﬁed DNA sequences in metho-
trexate-resistant cells.
Norbert Kartner further developed the theme that P-gp was
similar in diﬀerent MDR lines by generating a series of mono-
clonal antibodies using a dot blot assay on nitrocellulose to
screen for hybridoma clones producing antibodies able to rec-
ognize membrane proteins from diﬀerent species of mammalian
resistant cell lines but not sensitive ones. He isolated three clas-
ses of monoclonal antibodies [31], and their binding epitopes
were later deﬁned by Elias Georges [32]. One of them, C219, ap-
peared to recognize a highly conserved epitope, the c-terminal
half of P-gp, localized in the cytoplasmic domain. This mono-
clonal antibody was used by Jack Riordan to screen a k gt11
cDNA expression library from a derivative of CHR C5 cells
(CHRB30) thatNorbert had ‘‘bumped up’’ so that it could grow
in 30 lg/ml of colchicine. A 600 bp cDNA probe, k CHP1, was
isolated. The lacZ fusion product of k CHP1, which expresses a
C-terminal fragment of P-gp, is recognized by monoclonal anti-
bodies that identify three diﬀerent epitopes of P-gp. The South-
ern blot analysis of diﬀerent CHR lines revealed that the degree
of drug resistance correlated with the ampliﬁcation of k CHP1
homologous sequences and that P-gp is encoded by a multigene
family clustered in one amplicon [33]. Soon after these specula-
tions, Alexander Van der Bliek in Piet Borst’s group used pulse
ﬁeld gel electrophoresis to characterize this amplicon showing
that it contains at least 5 genes [34].
With the availability of a cDNA probe for P-glycoprotein,
we cloned and sequenced the 3 0 half of the P-gp cDNA from
the wild-type CHO cell line. The close similarity of this se-
quence with the bacterial hemolysin B transport protein
stunned us [35] and it caused us to formulate, by analogy to
hemolysin B, a functional model of P-gp as a multidrug eﬄux
pump. This led us and others to renew our eﬀort to purify,
reconstitute, and to investigate the properties of this remark-
able protein (see Refs. [12,13,36–38]). It seems clear that P-
gp can act alone as a multidrug transporter. What is not clear
is whether this transport function of P-gp is suﬃcient to ac-
count for other pleiotropic aspects of the MDR phenotype.
There is more to be learned.3. Molecular biology and mechanism of multidrug resistance
(1980–1990): Michael Gottesman and colleagues
When I joined NCI in 1976 as a senior investigator, my ﬁrst
goal was to establish somatic cell genetic systems for the study
of processes essential for cancer growth. My ﬁrst post-doc-
toral fellow, Fernando (Buz) Cabral was an expert in 2D gel
analysis, and I was experienced in developing drug-resistant
bacterial mutants. We reasoned that a robust cultured cell sys-
tem could be selected in anti-microtubule drugs frequently
used to treat cancer, and we would be able to use 2D gels
to determine what targets were mutated in the resistant cells.
Owing to the pioneering work of Theodore Puck (University
of Colorado) in developing Chinese Hamster Ovary (CHO)
cells as such a culture system, and thanks to the generosity
of Louis Siminovitch (University of Toronto), who had devel-
oped subclones of CHO cells that grew easily in suspension
and had also demonstrated the power of this system to facil-
itate isolation of somatic cell mutants, we decided to begin
with CHO cells. Our ﬁrst work resulted in the isolation of
b-tubulin mutants [39] that were temperature-sensitive for
growth [40] and we used the mutants to study spindle forma-
tion and how anti-microtubule drugs work in the treatment of
cancer.
In 1981, Ira Pastan (my lab chief in the Laboratory of
Molecular Biology, Division of Cancer Biology and Diagno-
sis, NCI) and I were approached by Bruce Chabner, Director
of the NCI’s Division of Cancer Therapy, who pointed out
that the real problem in treating cancer was not single agent
resistance, but MDR. I used to refer to this observation as
the ‘‘gospel of Bruce Chabner’’ – this appears in virtually
every paper on this subject in the opening words ‘‘Multidrug
resistance is a major impediment to the successful treatment
of cancer’’. Bruce asked Ira and I to consider working on
MDR and I became the leader of a small group dedicated
to determining the molecular basis of MDR in cancer. Alan
Rabson, our own Division Director, was a strong supporter
of this eﬀort, and we were given additional resources to attack
this problem. We wrote a strategic plan that emphasized
development of reagents suitable for use with human samples
so that we could apply our results immediately to human can-
cers. Our initial approach was to develop MDR cultured hu-
man cancer cells, use these to clone human MDR genes, and
develop diagnostic anti-human MDR gene product antibod-
ies. By this time, the MDR phenotype of cultured cells had
been described, and Rudy Juliano and Victor Ling [22] had al-
ready done their pioneering work on expression of P-gp in
MDR CHO lines, but it was by no means certain that P-gp
was the protein responsible for MDR, or that if it did contrib-
ute to MDR, that it was suﬃcient to confer the complete
MDR phenotype.
Shin-ichi Akiyama, a fellow in the lab, began by screening
human cultured cancer cells for two properties: high eﬃciency
of cloning and sensitivity to common MDR drugs such as col-
chicine, vinblastine and doxorubicin. Among a half dozen or
so cell lines we tested, one stood out – a line called KB which
was reported to be a human nasopharyngeal carcinoma. After
we began working with this line we discovered that it was actu-
ally a subclone of HeLa, a cervical adenocarcinoma cell line
that had contaminated and overgrown quite a few putative hu-
man cancer cell lines and had been acquired by ATCC and dis-
tributed as KB. To this day, HeLa (KB), owing to its robust
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useful human cancer cell line for studying development of drug
resistance.
Akiyama isolated many single-step clones of colchicine-resis-
tant KB cells [41]. We chose one such clone (KB-8) because it
was cross-resistant to the drugs of interest and then proceeded
to isolate other clones in multiple steps with increasing levels of
MDR, working only with those clones with similar patterns of
MDR in the hope of amplifying the gene or genes responsible
for this resistance pattern. This strategy was based directly on
the work of Robert Schimke (Stanford University) who had
shown that gene ampliﬁcation is a common mechanism of
drug resistance in cultured cells, and we hoped that amplifying
a gene would facilitate its eventual cloning. The KB cell line
series (KB-8, KB-8-5, KB-8-5-11 and subsequent, more resis-
tant populations such as KB-C1) have subsequently been
shown to overexpress only MDR1 among all 48 known ABC
transporters, supporting our original strategy for selection.
KB-8-5 was subsequently found to have a level of MDR1
expression similar to many human cancers [42]. Consequently,
these cells are still widely used as standards for human P-gp
expression by researchers and pharmaceutical ﬁrms through-
out the world. Surprisingly, we did not see signiﬁcant P-gp
expression in any of these cell lines as analyzed by Coomassie
Blue and silver staining of one-dimensional and two-dimen-
sional gels (no antibodies were as yet available to P-gp); this
result turned out to be due to technical problems associated
with detection of P-gp on Laemmli gels (see section above).
Once we had learned how to isolate MDR cell lines from
KB cells, we repeated these selections in the presence of vin-
blastine (KB-V series) and doxorubicin (Adriamycin)(KB-A
series). Having several diﬀerent selected cell lines, otherwise
isogenic, turned out to be a key element in the cloning of the
MDR1 gene.
While we were puzzling about the best way to isolateMDR1
genes overexpressed in our cell lines, I attended a Gordon Con-
ference in New Hampshire and at a poster session met Igor
Roninson, who was ﬁnishing his graduate studies with Alex
Varshavsky and had developed a generalizable technique for
cloning ampliﬁed genes from cultured cells. The technique in-
volved in-gel denaturation and renaturation of DNA that had
been treated with a restriction enzyme. The renaturation con-
ditions were set so that only highly ampliﬁed genes would be-
come double-stranded in the gel; single-stranded DNA could
then be digested with a single-strand speciﬁc nuclease. The
beauty of this technique was that with several diﬀerent MDR
cell lines we could look for ampliﬁed human genes that were
found in common and we found them in the KB cell lines
[43]. Roninson, working with David Housman and Varshav-
sky, had already demonstrated the utility of this technique in
MDR Chinese hamster cells [44]. Two kinds of human MDR
genes were found that we called MDR1 and MDR2 [43], but
an mRNA of 4.5 kb was only initially identiﬁed for the
MDR1 gene [45]. This was the beginning of a long and fruitful
collaboration with Igor Roninson, an extraordinarily creative
and consistently thoughtful colleague in the ﬁeld of MDR.
In the mouse and hamster, MDR genes were also being cloned
at around the same time in the laboratories of Victor Ling, Pe-
ter Melera (University of Maryland), Piet Borst (Netherlands
Cancer Center), and Philippe Gros (McGill University). There
are two mdr1-like genes in rodents and these came to be called
mdr1 and mdr3 in the mouse by Philippe Gros and pgp-1 andpgp-2 in the hamster by Victor Ling’s group. Susan Horwitz
(Albert Einstein College of Medicine) suggested the compro-
mise that the rodent mdr1-like genes be called mdr1a and
mdr1b, but there remains a diﬀerence of opinion about
whether MDR2 or MDR3 should be the name of the second
human MDR gene. When the human gene mapping organiza-
tion (HUGO) met to consider nomenclature of ABC genes,
MDR genes were called ABCB1 and ABCB4, a decision that
has certainly confused matters further.
Having a full-length MDR1 gene in hand allowed us to do
many critical experiments to answer the burning questions of
the day regarding MDR. The ﬁrst major question was whether
or not MDR1 encoded P-gp. We collaborated with the Ling
lab to demonstrate that the protein product of theMDR1 gene
was indeed P-gp in a little referenced, but critical paper pub-
lished in the BBRC [46]. As can be well-imagined, there were
high level discussions about authorship of this short manu-
script, and we settled on having NCI fellows including Kazu
Ueda, a brilliant post doc in our lab who had created the ﬁrst
full-length expressing clone of human P-gp, occupy the ﬁrst
author slots, and Victor and Jack Riordan, a longtime collab-
orator of the Ling laboratory, as the ﬁnal authors. This man-
uscript brought some important order to the MDR ﬁeld by
marrying the molecular biology with the biochemistry and
demonstrating that it was okay for competitors to collaborate.
The second major question was whether MDR1 (P-gp) was
able to confer the entire phenotype of multidrug resistance. As
noted, Kazu Ueda had created a full-length clone in a retro-
viral expression system [47] and in short order was able to
show that individual transfectant cell lines were fully multi-
drug-resistant. Our paper appeared a few months after a sim-
ilar demonstration by the Gros lab using mouse mdr1 [48],
which was a bit of a disappointment, since we thought this
was probably our most important contribution to date. Phi-
lippe Gros, starting his career as an Assistant Professor in
McGill, was thinking about MDR in much the same way that
we were and continued for several years to produce interesting
and important papers focusing on mouse mdr1a and mdr1b
genes.
Given that we had undertaken our studies on MDR with the
intent of applying them to human cancers, we moved quickly
to determine in what tissues MDR1 was normally expressed
and whether it was expressed in human cancers at levels that
could lead to MDR. Another collaboration, with Takashi
Tsuruo of the Tokyo Chemotherapy Center, proved to be crit-
ical here. Tsuruo’s lab had been a pioneer in showing that
verapamil could reverse MDR [49] (verapamil was later shown
to be a substrate and competitive inhibitor of P-gp), and he
had also produced a monoclonal antibody, MRK16, that spe-
ciﬁcally detected human P-gp [50]. Unlike the anti-hamster P-
gp monoclonal antibody, C219, which was the only other
antibody available at the time but was not absolutely speciﬁc
for P-gp, MRK16 did not detect any other proteins and
seemed ideal for our purposes. Tsuruo was very generous with
the antibody and coauthored with us the ﬁrst paper describing
the pattern of human P-gp expression in the apical portion of
intestinal, liver, and kidney epithelia [51,52]. None of this
immunohistochemistry would have been possible without the
leadership of Mark Willingham, a longtime collaborator of
Ira Pastan’s in the Laboratory of Molecular Biology, NCI,
who was a wizard with microscopes and imaging. This work
also illustrated the power of tapping the multidisciplinary team
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The localization result was conﬁrmed by another outstand-
ing fellow in the lab, Tito Fojo, using molecular analysis with
cDNA probes to detect mRNA [53]. Tito was a clinical fellow
in the NCI who had chosen to do research with Ira Pastan
and me, and proved to be an extremely productive and inno-
vative MDR investigator who focused on clinical relevance of
our experiments. Another such fellow, Lori Goldstein, was
assigned the task of determining whether MDR1 was ex-
pressed in human cancers. She collected close to 1000 human
cancers, developed tools for isolation of non-degraded
mRNA from these tumor samples, and learned how to quan-
titate mRNA on a slot blot. The success of these experiments
[42] showed that MDR1 was expressed at levels judged to be
suﬃcient to confer MDR in many epithelial cancers derived
from tissues that were known to express MDR1 (colon, liver,
kidney), was found in hematopoeitic cancers (AML, ALL.
lymphoma) and solid tumors (breast, ovary) that had re-
lapsed after chemotherapy with P-gp-aﬀected agents, and also
appeared occasionally in cancer simply as a result of the
transformation process. One important assumption made
throughout these studies was that the expression of MDR1
mRNA would correlate with functional P-gp; subsequent
studies have shown this to be correct with few, if any, excep-
tions. However, we have come to believe strongly that local-
ization of P-gp should be demonstrated by two techniques
before the result can be taken seriously; one of these should
be molecular, while the second could use an antibody to con-
ﬁrm that the protein is on the plasma membrane, where it
can be functional.
Based on these expression studies and others done in our lab
and elsewhere, Ira Pastan and I speculated that P-gp had
evolved as a general protection mechanism to keep toxic xeno-
biotics out of the body (intestinal barrier), to excrete such
xenobiotics from the kidney and liver if they were absorbed,
and to protect vulnerable tissues from circulating toxins
(blood–brain, blood–testis/ovary, and placental barriers). This
hypothesis was ﬁrst enunciated by Thiebaut et al. [51], and in a
review for the New England Journal of Medicine that we wrote
[54] and has become a central part of the P-gp dogma. Phar-
maceutical and academic interest in the eﬀect of polymor-
phisms of P-gp on the pharmacokinetics of many common
drugs derives directly from this hypothesis. Later, we produced
transgenic mice in which MDR1 was overexpressed in bone
marrow, and showed that this expression did, indeed, protect
mouse tissues from toxic levels of xenobiotics [55].
The studies on expression of P-gp in tumors and normal
tissues led naturally to questions about how this expression
was regulated. Kazu Ueda was particularly interested in this
issue and isolated the downstream MDR1 promoter [56]. This
promoter has since been analyzed in much more detail by
Kathleen Scotto (Fox Chase Cancer Center) and her col-
leagues, among others [57], but one interesting discovery at
the time was that in some of our KB-MDR cell lines the
majority of transcription came from a distant upstream pro-
moter [58]. In more recent independent work, Tito Fojo and
colleagues have shown that rearrangements involving this up-
stream promoter frequently occur in drug-resistant cancers,
providing the most convincing direct evidence to date that
selection for MDR1 expression occurs in vivo in human can-
cers [59].Although the molecular biology of the MDR1 locus was
being pursued in the laboratories of Piet Borst, Phillipe Gros,
and Igor Roninson by 1986, not much was known about how a
single protein could confer resistance to so many diﬀerent
drugs. The original designation of P-gp was based on the
assumption that this protein somehow blocked uptake of
many diﬀerent anti-cancer drugs (P stood for permeability in
the original Ling and Juliano work), but it was clear that the
major mechanism of resistance was increased drug eﬄux
[7,60]. This mechanism suggested that P-gp could bind drugs
directly, and we set out to demonstrate this. The initial studies
done by Marilyn Cornwell in our lab showed speciﬁc binding
of vinblastine to membrane vesicles containing P-gp, but it be-
came clear that we needed a photoaﬃnity label to directly
demonstrate binding of drugs to the putative transporter. Once
again, a collaboration with two NCI investigators, Ron Fel-
sted and Ahmed Safa, proved crucial. Safa had appreciated
the need to develop photoaﬃnity analogs of vinblastine for
use in studying binding to tubulin, its major intracellular tar-
get, and worked with us to adapt this system for studies of
P-gp [61]. In similar fashion, Cornwell demonstrated binding
of ATP to P-gp [62] and later, Ursula Germann showed ATP-
ase activity in membranes containing P-gp [63]. The P-gp bac-
ulovirus that Germann created in our lab turned out to be an
extremely useful reagent for Balazs Sarkadi (National Medical
Center, Hungary), an expert on ATPases, who has done some
elegant work on ATPases associated with P-gp and several
other ABC transporters [64]. With drug binding and ATPase
activity demonstrated for P-gp, it seemed increasingly likely
that it was the energy-dependent transporter responsible di-
rectly for MDR.
One missing piece of data was whether P-gp could act alone
to transport drugs. Hypotheses about P-gp working indirectly
by aﬀecting membrane potential or proton transport were pro-
posed in the literature, and although these seemed unlikely
based on the amount of drug being transported and the lack
of pH or potential gradients in many MDR cell lines, we
sought direct evidence that pure P-gp could transport drugs
in isolated membrane vesicles. Another talented Japanese fel-
low, Masuro Horio, trained in transport physiology, was able
to show that inside-out membrane vesicles containing P-gp
could transport drugs into the vesicle [65], but it required the
biochemical skill of another colleague, Suresh Ambudkar, then
at Johns Hopkins but eventually to become a senior investiga-
tor and highly valued colleague in the Laboratory of Cell Biol-
ogy, NCI, to reconstitute puriﬁed P-gp into vesicles and
demonstrate transport and ATPase activity [66]. Similar stud-
ies were done with highly puriﬁed P-gp in Ling’s lab by Shap-
iro ([36,37]; see above). Horio, in a collaboration with another
NIH colleague and transport expert Joe Handler, also showed
that P-gp could catalyze transepithelial transport in both
transfected [67] and naturally occurring cell lines [68]. This as-
say, using dog, pig, or human kidney cells, is now a standard
test for transepithelial transport by P-gp and other ABC trans-
porters whose expression is polarized.
How did P-gp recognize so many diﬀerent substrates?
Although we and others have done detailed mutational analy-
ses to identify important residues that aﬀect substrate speciﬁc-
ity and it was clear that even a single point mutation could
change substrate speciﬁcity [69], everyone was having trouble
understanding the apparent promiscuity of the transporter.
Once again, a collaborator came to our rescue. Yossi Raviv,
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Blumenthal, another NCI senior investigator, was looking
for systems to study with a non-speciﬁc, hydrophobic aﬃnity
probe (INA or iodonaphthalene azide). This probe, after UV
activation, labeled most proteins with transmembrane seg-
ments, and, indeed, in control experiments, P-gp was heavily
labeled by 131I-INA. Raviv worked out a way to indirectly la-
bel proteins that interact with chromophores; we showed that
daunorubicin, when photoactivated, could transfer energy to
INA which would speciﬁcally label P-gp [15]. Since INA is
only present in hydrophobic regions of membranes, the inter-
action of daunorubicin with P-gp must have been within the
plasma membrane. This observation resulted in two models
that have inﬂuenced mechanistic thinking about P-gp and sev-
eral other ABC transporters: the hydrophobic vacuum cleaner
model [15] and the ﬂippase model [14]. In the hydrophobic vac-
uum cleaner model, drugs are detected and extruded from the
lipid bilayer into an aqueous environment; thus, P-gp is eﬀec-
tively a phase separator that takes drugs from a hydrophobic
environment and places them in an aqueous environment.
The ﬂippase model, that derived directly from conversations
with Robert Blumenthal, an NCI biophysicist who pointed
out to me the resemblance of the drug transport process to li-
pid ﬂipping, proposes that drugs from the inner leaﬂet are
ﬂipped to the outer leaﬂet by P-gp, where they can diﬀuse into
the aqueous environment around the cell, or bind to proteins
such as albumin, present in medium. In practice, there is no
easy way to distinguish these two models, since drugs are in
very rapid equilibrium between the extracellular environment
and the outer leaﬂet of the plasma membrane. Experimental
evidence from many diﬀerent systems has since conﬁrmed that
one of these two models is likely correct.
As the 1980s came to a close, we began to think about ways
to exploit our knowledge about P-gp. We were told by our col-
leagues who were oncologists that cancers seemed able to eas-
ily develop MDR, but normal tissues never became resistant to
the toxic eﬀects of chemotherapy. So we set about to use P-gp
vectors to protect normal tissues against cytotoxic MDR sub-
strates, and to use these vectors to enable selection of other-
wise non-selectable genes [55,70,71]. Detailed clinical studies
on the role of P-gp in individual human cancers were obviously
essential, and depending on the outcome of these studies, eﬀort
needed to be devoted to develop agents that were not P-gp sub-
strates (evasion of P-gp), other drugs that were inhibitors of P-
gp (engagement of P-gp), or drugs that speciﬁcally kill P-gp
expressing cells (exploiting the Achilles heel of P-gp) [72].
These concepts were reviewed recently in Szakacs et al. [73].4. Concluding remarks
It has been 30 years since the discovery of P-gp. We welcome
this opportunity to reﬂect on some of the early work and espe-
cially on those deﬁning moments that caused us to change our
perspective. This is a story of convergence, of diﬀerent research
approaches and concepts. The Ling lab used somatic cell
genetics to investigate the properties of colchicine resistance
in Chinese hamster ovary cells. This resulted in linking P-gp
to MDR. The Gottesman lab used molecular biology to clone
ampliﬁed DNA sequences associated with the MDR pheno-
type in cell lines. Both approaches converged and the P-gp
gene and the MDR gene were subsequently shown to be thesame [46]. This has led to the current acceptance of P-gp as
an eﬄux pump of broad speciﬁcity providing an explanation
of the molecular basis for multidrug resistance. At the same
time, the lack of expression of P-gp in some multidrug-resis-
tant cell lines, notably lung cancer cells, led to the search for
and discovery of the second ABC transporter that confers mul-
tidrug resistance, MRP1 ([74]; also see chapter by Deeley and
Cole in this volume). This is a story of how science progresses,
by collaboration of creative individuals and by adoption of
new technologies as they emerge to answer questions of imme-
diate interest and importance.
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